+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Sarcoma

  • ID: 4462140
  • Report
  • December 2019
  • Region: Global
  • 57 Pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The author estimates that in 2017, there were approximately 413,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 485,100 incident cases by 2026.
  • Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (83%), while a smaller proportion were osteosarcomas and other malignant bone tumors (17%).
  • The approved drugs in the sarcoma space focus on a wide variety of targets. The majority of approved drugs are administered via the intravenous route, with two products being available in oral formulations.
  • The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II, with only one drug in the NDA/BLA stage.
  • Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular/subretinal/subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, and topical formulations.
  • High-impact upcoming events in the sarcoma space comprise topline Phase II trial results for ADP-A2M4CD8 and an expected PDUFA date for tazemetostat.
  • The overall likelihood of approval of a Phase I sarcoma asset is 10.7%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
  • There have been 17 licensing and asset acquisition deals involving sarcoma drugs during 2014-19. The largest deal during the period was the $1,150m strategic collaboration and licensing agreement signed in 2014 between Adaptimmune and GlaxoSmithKline to develop and commercialize Adaptimmune’s NY-ESO-1 program.
  • The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 89% of trials in Phase I-II, and only 11% in Phase III-IV.
  • The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major EU markets, while Israel has the top spot in Asia
  • Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 19 trials each.
  • Merck & Co leads ind
Note: Product cover images may vary from those shown
2 of 2
Contents

Overview

Key Takeaways

Disease Background
  • Subtypes
Treatment
  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapies
Epidemiology
  • Epidemiological disease definition
Marketed Drugs

Pipeline Drugs

Recent Events and Analyst Opinion
  • ASP7486 for Sarcoma (July 15, 2019)
  • Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Tazemetostat for Sarcoma (June 3, 2019)
  • Lartruvo for Sarcoma (June 2, 2019)
  • Hensify for Sarcoma (April 4, 2019)
  • Lartruvo for Sarcoma (January 18, 2019)
  • Beleodaq for Sarcoma (January 17, 2019)
  • Tazemetostat for Sarcoma (September 24, 2018)
  • Yondelis for Sarcoma (June 4, 2018)
  • Xpovio for Sarcoma (June 1, 2018)
Key Upcoming Events

Key Regulatory Events
  • Epizyme Banks On ORR For Tazemetostat Accelerated Approval
  • Celgene Eyes Late 2019 Kaposi Sarcoma Submission For Pomalyst Following BTD
  • Nanobiotix's Hensify Earns CE Mark For Soft-Tissue Sarcoma
  • EU Safety Review Starts For Oral Anticoagulants
  • Lilly's Lartruvo Could Be Headed For Rare Accelerated Approval Withdrawal
  • No New Patients For Lartruvo In EU After Trial Failure
Probability of Success

Licensing and Asset Acquisition Deals
  • STA Acquires Australian, Asian Rights To Yondelis
  • Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
Parent Patents

Revenue Opportunity

Clinical Trial Landscape
  • Sponsors by status
  • Sponsors by phase
  • Recent events
Bibliograpy
  • Prescription information
Appendix

List of Figures
Figure 1: Trends in incident cases of sarcoma, 2017–26
Figure 2: Incident cases of sarcoma, by age, 2017
Figure 3: Incident cases of sarcoma, by tumor type, 2017
Figure 4: Overview of pipeline drugs for sarcoma in the US
Figure 5: Pipeline drugs for sarcoma, by company
Figure 6: Pipeline drugs for sarcoma, by drug type
Figure 7: Pipeline drugs for sarcoma, by classification
Figure 8: Bempegaldesleukin for Sarcoma (June 3, 2019): Phase II - w/Nivolumab
Figure 9: Tazemetostat for Sarcoma (June 3, 2019): Phase II - INI1-Negative Tumors
Figure 10: Lartruvo for Sarcoma (June 2, 2019): Phase III - ANNOUNCE (w/Doxorubicin)
Figure 11: Yondelis for Sarcoma (June 4, 2018): Phase III - TSAR
Figure 12: Xpovio for Sarcoma (June 1, 2018): Phase II/III - SEAL
Figure 13: Key upcoming events in sarcoma
Figure 14: Probability of success in the sarcoma pipeline
Figure 15: Licensing and asset acquisition deals in sarcoma, 2014–19
Figure 16: Parent patents in sarcoma
Figure 17: Clinical trials in sarcoma
Figure 18: Top 10 drugs for clinical trials in sarcoma
Figure 19: Top 10 companies for clinical trials in sarcoma
Figure 20: Trial locations in sarcoma
Figure 21: Sarcoma trials status
Figure 22: Sarcoma trials sponsors, by phase

List of Tables
Table 1: Incident cases of sarcoma, 2017–26
Table 2: Marketed drugs for sarcoma
Table 3: Pipeline drugs for sarcoma in the US
Table 4: ASP7486 for Sarcoma (July 15, 2019)
Table 5: Bempegaldesleukin for Sarcoma (June 3, 2019)
Table 6: Tazemetostat for Sarcoma (June 3, 2019)
Table 7: Lartruvo for Sarcoma (June 2, 2019)
Table 8: Hensify for Sarcoma (April 4, 2019)
Table 9: Lartruvo for Sarcoma (January 18, 2019)
Table 10: Beleodaq for Sarcoma (January 17, 2019)
Table 11: Tazemetostat for Sarcoma (September 24, 2018)
Table 12: Yondelis for Sarcoma (June 4, 2018)
Table 13: Xpovio for Sarcoma (June 1, 2018)
Table 14: Historical global sales, by drug ($m), 2014–18
Table 15: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll